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Sobserved. Longer follow-up of a larger number of patients will be ready for presen-
tation in October.
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Background: We previously reported the results of the WAVE 1 trial for Renal
Sympathetic Denervation in twenty-four patients with refractory hypertension using
the Kona Surround Sound System. Six month results demonstrated a 27mmHg
reduction in systolic blood pressure in the study. This technology utilizes external
focused ultrasound navigated by a targeting catheter in the renal artery. The WAVE 1
protocol involved making 18 focused lesions over 12.6 minutes on each side. This
study (WAVE II) is evaluating the safety and efﬁcacy of an optimized treatment
protocol in which 14 focused lesions produced over 2.8 min on each side were utilized
to create sympathetic denervation.
Methods: Thirteen patients (8 men and 5 women; median age: 60 years), with
resistant arterial hypertension underwent bilateral externally focused ultrasound
utilizing a 5F intravascular catheter for targeting and tracking. Patients were on
a minimum of three antihypertensive medications. All treatments were performed in
patients under deep analgesic-sedation. The procedure was performed using the
2.8 min protocol for each side and targeting was directed to just proximal to the
bifurcation of the renal artery.
Results: During and after the procedure no serious complications were observed.
Unlike the WAVE I trial, only one of 13 patients complained of back pain following
the index procedure and this resolved within 4 days. To date, Eight patients reached
the 6-week follow up time point and Systolic BP decreased by 18 mmHg and diastolic
BP was unchanged.
Conclusions: The optimized externally focused ultrasound protocol was efﬁcient and
well tolerated. There were not serious adverse events reported and 6 weeks results for
eight patients were tracking similarly as patients treated in the WAVE I study which
ultimately resulting in a 27 mmHg reduction in systolic BP. Since externally focused
ultrasound can be performed safely, quickly, and effectively, the development of
a fully non-invasive system should offer even greater beneﬁts for patient care.
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Background: Resistant hypertension remains a major health concern despite the
availability of effective pharmacological agents. Catheter-based renal sympathetic
denervation has emerged as a therapeutic option for patients with resistant hyper-
tension. Recent clinical reports show that ablation of the renal sympathetic nerves
using radiofrequency (RF) energy is safe and effective. The OneShot Renal
Denervation System (Covidien, Campbell, CA) is a balloon-based RF system using
a mounted spiral electrode with a unique feature of irrigation of the vessel wall-
during treatment. The non-compliant balloon is inﬂated under low pressure (1 atm)
in the renal artery, and the electrode delivers RF energy with a single 2-minute
treatment.
Methods: RAPID is a prospective, multicenter, single-arm study that enrolled 50
patients at 11 clinical sites in Europe and New Zealand. Patients were considered for
enrollment based on having an ofﬁce systolic blood pressure (SBP) 160 mmHg
despite treatment with a regimen three or more antihypertensive medications including
a diuretic.The follow-up period is at 1, 3, 6, 12, 24 and 36 months. The primary safety
endpoints include acute procedural safety, deﬁned as the overall rate of serious
adverse events (SAEs) and adverse device effects (ADEs) at discharge; and chronic
procedural safety, deﬁned as the overall rate of SAEs and ADEs at 6 months. The
primary effectiveness endpoint is the rate of ofﬁce systolic blood pressure reduction
> 10 mmHg at 6 months compared to baseline.
Results: Fifty patients were enrolled with a mean age of 63.0 years (58.0% male).
Patients were on a mean of 4.9 antihypertensive drugs at baseline. The mean baseline
ofﬁce systolic and diastolic blood pressure measurements were 181.6  20.8 and
95.5  15.5 mmHg, respectively.Results at 1 month showed a signiﬁcant reduction,
-17/-7 mmHg (p<0.0001 and p¼0.0008), in both systolic and diastolic blood pressure
measurements. An update of the ongoing study endpoint results will be presented at
TCT.
Conclusions: Preliminary results of the RAPID study demonstrate safe delivery of RF
energy for renal sympathetic denervation.B20 JACC Vol 62/18/Suppl B j October 27–November 1, 2013 jTCT-63
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Background: The restenosis rate of stents is still a major limitation of arterial
interventions. The Freeway Stent Study investigates the inhibition of restenosis by
Paclitaxel-eluting balloon dilatation post stent PTA versus stenting PTA with plain
balloon postdilatation in the treatment of the superﬁcial femoral artery. By this, the
Freeway Stent Study follows a new approach to potentially overcome the problem of
restenosis.
Methods: The Freeway Stent Study is a randomized, controlled multicenter trial
which is conducted in 15 centers in Germany and Austria. This study intends to enroll
200 patients being randomized in a 1:1 relation to either nitinol stenting followed by
drug-coated balloon FreewayTM (Eurocor GmbH) postdilatation or stenting with
plain balloon post dilatation. Primary endpoint is clinically driven target lesion
revascularization at 6 months. Further, secondary safety and efﬁcacy endpoints such
as late lumen loss at 6 months, patency rate and major adverse events are investigated.
Results: 150 patients have already been enrolled. More than 100 have completed the 6
months follow up. The results show a favorable outcome for the DCB arm in relation
to the TLR rate in this patient population which presented predominately with
occlusions. The results are supported by the clinical outcome of patency rate, ABI
index and presentation according to Rutherford.
Conclusions: In this trial the Freeway Paclitaxel-coated balloon is investigated in
a new approach to decrease the restenosis rate of stents in patients with stenting in the
SFA. Interim results will be provided to show that DCB might provide an advantage
also in these patients to overcome the existing limitations of peripheral artery disease
treatment.
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Are Stent Grafts The Solution For In-Stent Restenosis After SFA Stenting
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Background: Tackling in-stent restenosis (ISR) in the superﬁcial femoral artery
(SFA) has some challenges. To date literature review reveals only very limited data
on ISR in peripheral arteries. Current available treatments do not yield satisfactory
results, demonstrating the need of a treatment with a better outcome. The Viabahn
endoprosthesis with a heparin bioactive surface offers high ﬂexibility when
deployed in the SFA and the coating provides an enhanced hemocompatibility.
Methods: The RELINE trial is a prospective, randomized, multi-center, international,
controlled trial in which enrollment was allowed to continue until 80 patients meet the
eligibility criteria. Between June 2010 and February 2012, 100 patients were enrolled.
The ﬁrst primary endpoints is primary patency at 12 months, deﬁned as no evidence of
restenosis or occlusion within the originally treated lesion based on color-ﬂow duplex
ultrasound (CFDU) measuring a peak systolic velocity ratio 2.5 and without target
lesion revascularization (TLR) within 12 months. The second primary endpoint is the
proportion of subjects who experience serious device-related adverse events within 30
days post-procedure.
Results: The preliminary analysis is based on the intention-to-treat total of 100
patients. 47 (47.0%) patients were randomized to the VIABAHN ISR group and
53 (53.0%) patients were randomized to the POBA group. The demographic data
was comparable in both treatment groups. In the VIABAHN ISR group there were
34 (72.3%) men and the mean age was 67.34 (49-86) years. In the POBA group,
35 (66.0%) patients were male and the mean age was 69.26 (48-87) years. The
survival analysis shows a primary patency rate at 6 months of 94.4% for the
VIABAHN ISR group and 60.7% for the POBA group (p<0.001). Freedom of
TLR at 6 months is 94.3% in the VIABAHN ISR group and 60.4% in the POBA
group (p<0.001). These data are preliminary, indicated by the 24 patients at risk
in the VIABAHN ISR group and 14 patients at risk in the POBA group at 6
months.
Conclusions: With very good, but preliminary results, the full 12 months data anal-
yses are expected to be able to show a similar trend in patency outcome, which will
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Background: The endovascular treatment of infrapoplitealarterial disease in patients
with critical limb ischemia (CLI) is complex and seldom studied. Directional athe-
rectomy (DA) revascularizes by removing the atherosclerotic plaque and minimizing
the need for balloon angioplasty and/or stenting. The DEFINITIVE LE study wasTCT Abstracts/ORAL/Renal Denervation and Endovascular Intervention





Sa multinational study that assessed the effectiveness of DA using the SilverHawkTM
and TurboHawkTMPlaque ExcisionSystems (Covidien/ev3, Plymouth, MN) for
treatment of peripheral arterial disease.
Methods: The DEFINITIVE LE study enrolled 800 patients. Of those, 70 had CLI
and at least one infrapopliteal target lesion treated with DA. Endpoints and adverse
events were assessed by independent core laboratories and a Clinical Events
Committee. The primary endpoint for the CLI cohort was freedom from major
unplanned amputation of the target limb at 12 months.
Results: Within the DEFINITIVE LE study, 70 patients with CLI had 96 infrapo-
pliteal target lesions treated with DA. The breakdown by Rutherford Clinical Category
(RCC) was as follows: RCC 4: 34%, RCC 5: 63%, and RCC 6: 3%.The mean age
was74 years, 56% were male and79% had diabetes.The mean lesion length was 6.0
cm and the mean baseline stenosis was 77%. One-third (33%) of lesions were
occluded,31% of lesions were calciﬁed and 39% had inﬂow disease treated during the
same procedure.Periprocedural complications included 1 (1%) perforation and 3 (4%)
embolizations; there were no ﬂow-limiting dissections. At 12 months, limb salvage
was 94%, primary patency was 78% and freedom from target lesion revascularization
(TLR) was 87%, per Kaplan-Meier estimates. Complete wound healing at 12 months
was 68%.
Conclusions: This prospective assessment of DA for treatment of Infrapopliteal
lesions in CLI patients showed low complication rates and high rates of limb salva-
ge,freedom from TLR, and primary patency at 12 months comparable to recent drug
eluting stent trials. These ﬁndings should be taken into consideration when treating
this challenging group of patients.
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Background: The natural history of patients with intermittent claudication (IC) has
been reported. However, little is known about prognosis of claudicant patients after
endvascular therapy (EVT).
Methods: This study was performed as a large-scale multicenter, retrospective
registry. A total of 2,930 consecutive patients (mean age, 71.58.9 years, 78.7%
male) with IC treated by EVT for a de novo ilio-femoral lesion were enrolled. The
primary outcome measure was overall survival, and the secondary outcome measure
were freedom from major adverse cardiovascular events (MACE; all-cause death
(ACD), myocardial infarction and stroke), and major adverse cardiovascular and limb
events (MACLE; any repeat revascularization for limb and leg amputation in addition
to MACE).
Results: The overall survival rate was 97.2%, 90.8%, and 83.4% at 1, 3 and 5 years.
The cause of death was cardiovascular in 42.8%. Freedom from MACE (MACLE)
was 96.7% (84.5%), 88.6% (68.1%), and 77.3% (58.7%) at 1, 3and 5 years. On
multivariate analysis performed logistic regression by prespeciﬁed risk factors,
elderly age, Dialysis, LV dysfunction, Insulin administration, complication of
hematoma, Coronary artery disease, SFA plus iliac lesions were found to be positive
independent predictors of ACD. ACEI/ARB, Ca-antagonist administration were
negative predictor. Risk stratiﬁcation of ACD based on these seven positive
predictors. Elderly age, Dialysis, LV dysfunction, Insulin administration and
complication of hematoma were scored as 2 points. The others were assigned 1 point
each. The scores of 0 to 2, 3 to 5, and >6 points were classiﬁed as low-, moderate-
and high-risk patients, respectively. The overall survival rate was signiﬁcantly lower
in the high-risk patients than other two groups (90.1% vs. 78.6% vs. 53.5% at 5years,
P<0.0001; log-rank test).
Conclusions: The prognosis after EVT for patients with IC was relative good.
However, that for high risk patients with IC was extremely poor.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrInvasive Imaging
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Background: The EGO-COMBO study is the ﬁrst study ever designed to establish
the healing proﬁle of a DES, and beneﬁts of the dual therapy COMBO Stent
(OrbusNeich, US), a hybrid version of the EPC-capturing Genous Stent plus a 5mg/
mm abluminal sirolimus coating, using sequential OCT FUs to 24 months.
Methods: In this prospective single center study, 61 patients (9M DAPT) received 3
longitudinal sequential OCTs at baseline (for optimal stent apposition), at early FU (4
monthly group 2nd to 5th month, in 1:2:2:1 ratio, for % strut coverage using 6
Categories), then at 9M (for late loss and OCT neointima), and clinical FU to 12M.
With a 2nd approved protocol, a 24M OCT FU was initiated for long term outcomes.
All clinical event adjudication, QCA & OCT analyses were undertaken by CRF Core
Lab., NY.
Results: 61 patients (33% DM) received 88 COMBO stents (size 3.060.39mm &
length 23.97.62mm). Early strut coverage (OCT Cat. D to F) increased from 84.3,
90.2, 90.5, to 92%; interpolated 100% coverage at 150 days. 9M OCT FU Rate was
100%; only 1 TLR treated by POBA (MACE Rate 1/61 ¼ 1.64%). 9M late loss was
0.240.36mm, OCT NIT 0.157mm & NIA 1.445mm2. At 24M, 1 case lost to FU
(migrated to China), another elderly patient died from VF after days of recurrent chest
pain without seeking advice. All remaining 59 cases were entirely asymptomatic & 18
declined the 4th OCT FU (24M Clinical FU Rate 58/59 ¼ 98.3% & OCT FU Rate 40/
58 ¼ 69.0%). To date, 39 patients have had the restudy, all showing excellent results
(late loss catch up <0.1mm; OCT NIT D 0.002mm; NIA D 0.13mm2), without
neoatherosclerosis or late stent thrombosis (not even micro-thrombi by OCT). Thus,
24M MACE Rate 2/61 ¼ 3.28%; ﬁnal core lab. results pending.
Conclusions: Using stringent longitudinal sequential OCT FUs with core lab. adju-
dication, the dual therapy COMBO stent is the ﬁrst DES ever with a healing proﬁle
established and appears to be a novel device (excellent healing with optimal neo-
intimal suppression without late stent thrombosis) with durable 24M outcomes. This
longitudinal sequential OCT FU approach may be adopted to guide development of
any new stent platform, appropriate DAPT duration, and to predict (prevent) late stent
thrombosis.
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Background: Whether IVUS guidance reduces the long-term rates of stent throm-
bosis (ST) after drug-eluting stent (DES) implantation is controversial.acts/ORAL/Invasive Imaging B21
